Premium
Protochemotherapy in non‐small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report
Author(s) -
Bitran Jacob D.,
Golomb Harvey M.,
Hoffman Philip C.,
Albain Kathy,
Evans Richard,
Little Alex G.,
Purl Sandy,
Skosey Connie
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860101)57:1<44::aid-cncr2820570111>3.0.co;2-h
Subject(s) - vindesine , medicine , etoposide , chemotherapy , lung cancer , cisplatin , lung , oncology , small cell carcinoma , survival rate , carcinoma , stage (stratigraphy) , surgery , gastroenterology , cyclophosphamide , vincristine , paleontology , biology
Twenty patients with Stage IIIM0 (T3N2) non‐small cell lung cancer were treated with vindesine, etoposide, and Platinol (cisplatin) (ELETOP) chemotherapy in an attempt to decrease tumor size and increase resectability and survival. ELETOP chemotherapy induced a 70% response rate (all partial responses) within 6 weeks, and three patients were able to undergo curative resection. Toxicities with ELETOP were moderately severe, with leukocyte and platelet nadirs on day 15. This pilot study demonstrates the feasibility of protochemotherapy in non‐small cell lung cancer.